212 related articles for article (PubMed ID: 27712076)
21. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
22. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Smith JA; Brown J; Martin MC; Ramondetta LM; Wolf JK
Gynecol Oncol; 2004 Jan; 92(1):314-9. PubMed ID: 14751176
[TBL] [Abstract][Full Text] [Related]
23. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.
He C; Liu D; Lin W
Biomaterials; 2015 Jan; 36():124-33. PubMed ID: 25315138
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
25. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
[TBL] [Abstract][Full Text] [Related]
26. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
[TBL] [Abstract][Full Text] [Related]
27. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
Van Moorsel CJ; Smid K; Voorn DA; Bergman AM; Pinedo HM; Peters GJ
Int J Oncol; 2003 Jan; 22(1):201-7. PubMed ID: 12469205
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
Berg T; Nøttrup TJ; Roed H
Gynecol Oncol; 2019 Dec; 155(3):530-537. PubMed ID: 31604664
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.
Wang X; Chen F; Gou S
Bioorg Med Chem; 2021 Jan; 29():115858. PubMed ID: 33218897
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
[TBL] [Abstract][Full Text] [Related]
32. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza AM; Matulonis UA; Alvarez Secord A; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ; Fleming GF; Markham MJ; Hirte HW; Provencher DM; Basu B; Kristeleit R; Armstrong DK; Schwartz B; Braly P; Hall GD; Nephew KP; Jueliger S; Oganesian A; Naim S; Hao Y; Keer H; Azab M; Matei D
Clin Cancer Res; 2020 Mar; 26(5):1009-1016. PubMed ID: 31831561
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of chemotherapy according to
Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
[TBL] [Abstract][Full Text] [Related]
35. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
[TBL] [Abstract][Full Text] [Related]
36. Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer.
Scarano W; de Souza P; Stenzel MH
Biomater Sci; 2015 Jan; 3(1):163-74. PubMed ID: 26214199
[TBL] [Abstract][Full Text] [Related]
37. Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Larson N; Yang J; Ray A; Cheney DL; Ghandehari H; Kopeček J
Int J Pharm; 2013 Sep; 454(1):435-43. PubMed ID: 23827653
[TBL] [Abstract][Full Text] [Related]
38. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Huang YH; Peng W; Furuuchi N; DuHadaway JB; Jimbo M; Pirritano A; Dunton CJ; Daum GS; Leiby BE; Brody JR; Sawicki JA
Oncotarget; 2016 Apr; 7(16):21812-24. PubMed ID: 26943573
[TBL] [Abstract][Full Text] [Related]
39. Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP).
Gallo D; Fruscella E; Ferlini C; Apollonio P; Mancuso S; Scambia G
Int J Gynecol Cancer; 2006; 16(1):222-30. PubMed ID: 16445637
[TBL] [Abstract][Full Text] [Related]
40. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Edelman MJ; Quam H; Mullins B
Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
